Intellia Therapeutics Stock Jumps as CRISPR Therapy Data Put FDA Filing in Focus
Intellia shares jumped 23% to $14.92 after Phase 3 data showed lonvo-z reduced hereditary angioedema attacks by up to 91% versus placebo; the next key catalyst is completion and FDA review of the rolling BLA for potential U.S. approval, with investors watching for regulatory progress and future product launch.